Please assess the completion status of the following clinical trial:

Trial Title: Effect of Saccharomyces Cerevisiae on Vulvo-vaginal Candidiasis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Subject suffering from a vulvo-vaginal candidiasis (according to clinical examination) characterized by a vaginal discharge associated with any of the following symptoms: itching and burning vaginal feeling, dyspareunia and dysuria.~* Amenorrheic subject, or subject having a regular menstrual cycle.~* Subject psychologically able to understand the study related information and to give a written informed consent.~* Subject having given freely and expressly her informed consent.~* Subject able to comply with protocol requirements, as defined in the protocol.~* Subject affiliated to a health social security system.~* Female subjects of childbearing potential should use a medically accepted contraceptive regimen (except latex condom, latex diaphragm, spermicidal) during the D0-D14 period, since at least 12 weeks before the beginning of the study, during all the study and at least 1 month after the study end, at the investigator's discretion~Exclusion Criteria:~In terms of population~* Pregnant or nursing woman or planning a pregnancy during the study.~* Post-menopausal women.~* Subject who will have her period between the first and the second visit to the gynaecologist (between D0 and D7).~* Subject who had been deprived of their freedom by administrative or legal decision or who is under guardianship.~* Subject in a social or sanitary establishment.~* Subject suspected to be non-compliant according to the investigator's judgment.~* Subject enrolled in another clinical trial on the same test zone within the four previous weeks and during the study period, being in an exclusion period for a previous study, having tested a food supplement or a medication in the 4 previous weeks.~* Subject in an emergency situation. In terms of associated pathology~* Subject with a condition or receiving a medication which, in the investigator's judgment, put the subject at undue risk.~* Subject suffering from systemic diseases using concurrent therapy that may interfere with the evaluation of the study results.~* Subject with a known allergy to one of the component of the study products or to the medication (vaginal ovule and/or antifungal cream).~* Subject presenting an hypersensitivity to any antifungal of imidazole family or to one of the excipient.~* Uterine or vaginal bleeding of unknown origin~* Subject with known sexually transmitted infections such as Neisseria gonorrhoea, Chlamydia trachomatis, Treponema pallidum, herpes simplex, Trichomonas vaginalis, human papilloma virus or HIV 1 or 2.~* Immunocompromised subjects~Relating to previous or ongoing treatment~• Subject undergoing a topical treatment on the test area or a systemic or intravaginal treatment:~* antibiotics currently or within the past 2 weeks (systemic antibiotic are accepted if the treatment was stopped until the day before the inclusion visit)~* anti-fungal agents currently or within the past 2 weeks,~* anticoagulant within the past 2 weeks and during the study,~* anti-inflammatory medication and/or anti-histamines during the previous 2 weeks and during the study,~* corticosteroids during the 2 previous weeks and during the study,~* retinoids and/or immunosuppressors during the 3 previous months and during the study,~* any medication stabilized for less than one month.~In terms of lifestyle~* Subject planning to change her usual hygiene habits and products during the study.~* Subjects not willing to stop taking probiotics dietary supplements and food products enriched with probiotics.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 50 Years
- Healthy Volunteers: f

Study Arms:
- Saccharomyces cerevisiae (Type: ACTIVE_COMPARATOR): Inactivated whole yeast Saccharomyces cerevisiae presented in vaginal capsules. 1 capsule a day for 14 days.
- Maize starch and magnesium stearate (Type: PLACEBO_COMPARATOR): Placebo presented in a vaginal capsule. 1 capsule a day for 14 days

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues